<?xml version="1.0" encoding="UTF-8"?>
<p>Pharmacological interventions have been proposed to prevent common respiratory virus infections. Intravenous immunoglobulins and palivizumab have been suggested for RSV infection prevention, but have not been evaluated in patients with HM. Prophylactic post-exposure oseltamivir therapy is currently recommended in patients with HM [
 <xref ref-type="bibr" rid="CR176_21">176</xref>]. This preventive measure has not been evaluated in randomised controlled trials, but seems safe based on a recent retrospective study in HSCT recipients [
 <xref ref-type="bibr" rid="CR177_21">177</xref>]. Considering the lack of proven benefits of oseltamivir therapy and the growing concern about the emergence of oseltamivir-resistant influenza strains, oseltamivir therapy should be carefully evaluated before it is suggested for use on a large scale [
 <xref ref-type="bibr" rid="CR130_21">130</xref>].
</p>
